Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Growth differentiation factor 15 in heart failure: an update.Curr Heart Fail Rep. 2012; 9: 337-345
- Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.Eur Heart J. 2009; 30: 2346-2353
- The association of growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients.PLoS One. 2012; 7: e46534
- Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts.Heart Vessels. 2013; ([Epub ahead of print])
- Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support.Eur J Heart Fail. 2012; 14: 1249-1256
- A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.J Am Coll Cardiol. 2013; 62: 263-271
- How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.Eur Heart J. 2007; 28: 2539-2550
- The epidemiology of heart failure: the Framingham Study.J Am Coll Cardiol. 1993; 22: 6A-13A
- Outcome of heart failure with preserved ejection fraction in a population-based study.N Engl J Med. 2006; 355: 260-269
- Trends in prevalence and outcome of heart failure with preserved ejection fraction.N Engl J Med. 2006; 355: 251-259
- Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.Can J Cardiol. 2012; 28: 62-68
- The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction.Eur J Heart Fail. 2010; 12: 1309-1316
- Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.Eur J Heart Fail. 2012; 14: 487-494
- Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women.Am J Cardiol. 2012; 110: 993-1000
- Albumin levels predict survival in patients with heart failure and preserved ejection fraction.Eur J Heart Fail. 2012; 14: 39-44
- B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.J Am Coll Cardiol. 2013; 61: 1498-1506
- Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.J Am Coll Cardiol. 2007; 50: 1054-1060
- Membrane-associated matrix proteolysis and heart failure.Circ Res. 2013; 112: 195-208
- The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.Circ Res. 2006; 98: 351-360
- GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation.Circ Res. 2006; 98: 342-350
- Macrophage inhibitory cytokine MIC-1 is upregulated by short-wavelength light in cultured normal human dermal fibroblasts.FEBS Lett. 2009; 583: 933-937
See editorial by Putko et al., pages 264-266 of this issue.
See page 343 for disclosure information.